Psoriatic Arthritis
Conference Coverage
Reduced-frequency methotrexate monitoring causes no harm
Laboratory blood test results were similar despite moving from once every month to about once every 3 months or about once every 5 months during...
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
From the Journals
Parents’ autoimmune diseases may affect children’s development
Type 1 diabetes and psoriasis in parents, and rheumatoid arthritis in mothers, are associated with increased risk for autism spectrum disorder and...
From the Journals
Long-term efficacy, safety data for ixekizumab in pediatric psoriasis reported
No new safety findings during weeks 48 to 108 of the trial were reported, including no new cases of inflammatory bowel disease or Candida...
From the Journals
Secukinumab’s antipsoriatic effects confirmed in U.S. patient population
Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in...
Latest News
Hypocaloric diet controls joint activity in psoriatic arthritis – regardless of weight loss
A hypocaloric diet in patients with psoriatic arthritis improved disease activity and body composition.
Latest News
International consensus reached on methotrexate dosing for psoriasis
“We hope to raise awareness on the different MTX dosages used in daily practice and the need for a more uniform dosing regimen.”
Conference Coverage
Apremilast has neutral effect on vascular inflammation in psoriasis study
“There has been a keen interest in understanding how psoriasis therapies impact cardiovascular risk.”
From the Journals
Medicare Part D beneficiaries without low-income subsidy less apt to fill prescriptions for pricey drugs
An analysis of more than 17,000 prescriptions written between 2012 and 2018 for Part D beneficiaries revealed that patients receiving subsidies...
From the Journals
Trial gives new guidance for choosing initial PsA treatment
Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than...
Latest News
Study links air pollution to psoriasis flares
The findings underscore the need for clinicians to “consider environmental/external triggers in patients with chronic inflammatory diseases...